- The all-stock merger between Foamix and Menlo has been badly received by the markets, but we beg to differ.
- Basically, the merger reduces cost, risk and leverages the critical sales infrastructure already 90% in place for the upcoming launch of AMZEEQ in January.
- There is a deal of uncertainty, as the post-merger ownership ratio depends a lot on the outcomes of two Phase III trials of Menlo’s Serlopitant.
- We think that uncertainty has been sensibly dealt with, as failure in one or both of these tests significantly reduces Menlo’s post-merger ownership stake.
The Foamix And Menlo Merger Makes Sense
December 10th, 2019 · No Comments